After a successful evaluation of its whole-genome sequencing-based test for solid tumor minimal residual disease (MRD) C2i Genomics announced today (January 5) that they have extended their collaboration with AstraZeneca.
A leader from healthcare commercial intelligence company Definitive Healthcare discusses the rise of precision medicine and the benefits the field can yield.
The health care system and analytics company are joining on the ASAP study, a program that constitutes a five-year commitment to advancing cancer solutions.
The academic research center has adopted the life science technology company’s cloud-based platform for cancer research, drug discovery, and clinical trials.
The Oxford-GSK Institute of Molecular and Computational Medicine has been created via a five-year collaboration between GlaxoSmithKline and the University of Oxford.
An advanced cancer detection platform from C2i Genomics (reportedly capable of spotting miniscule traces of the disease) recently landed $100m in funding.
One Health’s FidoCure is using genomics and AI technology to develop precision oncological treatments, and the work is benefiting human cancer research.
The two companies will work to advance precision cancer medicine by harnessing genomics data in trial design, recruitment, site selection and other areas
The analytical tool, developed via Bionano Genomics, maps structural variations in DNA that are known to cause disease and are tied to symptom severity.
A partnership between Immunai and 10x Genomics will use artificial intelligence to create a map of the immune system to help accelerate drug development.
Freenome is working with a CRO as part of a clinical trial evaluating the company’s multi-omics blood testing platform – which the CEO says helps de-risk drug development by characterizing likely responders to therapy, among other use cases.
Novogene is working with Mission Bio to offer customers in China access to the Tapestri Platform, which is being used in the drug development process by LabCorp and more than a dozen institutions.
Saga Diagnostics AB secures venture-backed financing to advance its precision oncology genomics testing technology, which is being used to monitor patient responses in clinical trials, among other applications.
The global genomic data and insights company expands its US footprint with the addition of a new genetic analysis laboratory as part of its mission to improve lives through genomics.
Iqvia says its collaboration with Genomics England will help drugmakers and academics draw insights from clinical-genomic datasets – the ‘future of real-world research.’
The FDA (US Food and Drug Administration) and Gene Logic are to
collaborate in developing a set of industry standards for genomic
data sent to the regulator.
A new genetic research method has revealed interesting insights
into drug metabolism, which could lead to a better understanding
drug selection and dosing regimens in humans.
